Two key late-stage studies of Pfizer's blockbuster pneumococcal vaccine for children show it works at least as well as a rival in adults, a big market the drugmaker wants to tap.
The studies of Pfizer Inc.'s Prevnar 13 vaccine against pneumonia, meningitis and other infections were presented Monday at two medical conferences in Milan, Italy. The results have been submitted to regulators in the U.S., European Union and more than a dozen other countries where New York-based Pfizer is seeking approval for people over 49.
It said the studies show the shots worked as well as or better than an older pneumococcal vaccine made by Merck & Co, Pneumovax 23.